Resilience partners with the California Institute for Regenerative Medicine to help cell therapy startups
As Resilience keeps up the momentum post-Series D, the biomanufacturer has reeled in another partnership, this time in the Golden State.
The company announced that it has been named by the California Institute for Regenerative Medicine (CIRM) as one of its initial industry resource partners within its industry alliance program (IAP).
The deal will have Resilience support translational and clinical phase grant applications, including TRAN, CLIN1 and CLIN2 grants, for cell therapy programs. The deal also has the potential to expand to other modalities such as gene therapies and biologics in the future. Resilience will provide project consultation that could aid CIRM applicants in drafting manufacturing plans and budgets for their applications to the program.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.